Lakefront Biotherapeutics NV (GLPGN) Income Statement
Lakefront Biotherapeutics NV Income Statement
Last quarter (Q1 2026), Lakefront Biotherapeutics NV's total revenue was $6.48M, a decrease of 91.36% from the same quarter last year. In Q1, Lakefront Biotherapeutics NV's net income was $14.49M. See Lakefront Biotherapeutics NV’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 1.11B | $ 275.65M | $ 239.72M | $ 505.28M | $ 484.85M | |
| $ 1.03B | $ 240.79M | $ 203.74M | $ 493.20M | $ 483.22M | |
| $ 561.00M | $ 429.12M | $ 327.99M | $ 760.72M | $ 648.81M | |
| Depreciation and Amortization | $ 51.86M | $ 45.50M | $ 43.64M | $ 65.57M | $ 21.30M |
| $ 521.51M | $ 43.33M | $ 51.04M | $ 3.87M | $ -100.93M | |
| $ 469.66M | $ -188.34M | $ -88.26M | $ -267.52M | $ -165.60M | |
| $ -168.79M | $ 185.25M | $ 93.89M | $ 60.21M | $ 48.57M | |
| $ 300.87M | $ -3.08M | $ 5.63M | $ -215.15M | $ -123.00M | |
| $ 320.88M | $ 74.08M | $ 211.70M | $ -217.99M | $ -125.42M | |
| Per Share Metrics | |||||
| Basic EPS | $ 4.87 | $ 1.12 | $ 3.21 | $ -3.32 | $ -1.91 |
| Diluted EPS | $ 4.87 | $ 1.12 | $ 3.21 | $ -3.32 | $ -1.91 |
| Weighted Average Shares Outstanding | 65.89M | 65.90M | 65.88M | 65.70M | 65.50M |
| Weighted Average Shares Outstanding (Diluted) | 65.89M | 65.90M | 65.88M | 65.70M | 65.50M |
Currency in EUR